US House Cosmetics Hearing: Preemption, FDA Ingredient Review Could Be Regulatory Reform Snags
Federal preemption of state and local requirements that differ from federal mandates came up repeatedly at the House Energy & Commerce Health Subcommittee’s 4 December cosmetics hearing. Meanwhile, both NGO and industry stakeholders generally support FDA review of cosmetic ingredients, but the details of such a framework likely will be contentious as work progresses.
You may also be interested in...
While other legislative proposals to update US cosmetics regulations would have included FDA ingredient review or codified reviews from the CIR Expert Panel for Cosmetic Ingredient Safety, the Modernization of Cosmetic Regulations Act of 2022 does not. Panelists, industry and FDA reps discussed implications for CIR at the 5-6 March meeting of the group’s independent expert panel.
In HBW Insight’s conversations with industry advocates about legislation in the US Senate to reform US cosmetics regulations, frustrations with the process have been palpable. Stakeholders suggest that science and proportionality are taking back seats to politics and that concerns about costs to industry, which ultimately could be passed on to consumers, are not being taken seriously enough.
Bundled within the draft FDA Safety and Landmark Enhancements Act are federal cosmetics reform provisions that would require facility registration and product listings with the US FDA, adverse event reporting and good manufacturing practices, while empowering the agency to order product recalls, access company records, and suspend dangerous operations.